Intervention Review

You have free access to this content

Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes

  1. Xavier Bosch1,*,
  2. Jaume Marrugat2,
  3. Juan Sanchis3

Editorial Group: Cochrane Heart Group

Published Online: 8 NOV 2013

Assessed as up-to-date: 9 MAY 2013

DOI: 10.1002/14651858.CD002130.pub4


How to Cite

Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD002130. DOI: 10.1002/14651858.CD002130.pub4.

Author Information

  1. 1

    Hospital Clinic, University of Barcelona, Department of Cardiology, Barcelona, Spain

  2. 2

    Municipal d'Investigacio Medica, Program of Research in Inflammatory and Cardiovascular Disorders (RICAD) Institut, Barcelona, Spain

  3. 3

    Hospital Clinic, Department of Medicine, University of Valencia, Cardiology Department, Valencia, Spain

*Xavier Bosch, Department of Cardiology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Villarroel 170, Barcelona, 08036, Spain. xbosch@clinic.ub.es. xbosch@clinic.ub.es.

Publication History

  1. Publication Status: Edited (conclusions changed)
  2. Published Online: 8 NOV 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Figure 3]
Figure 3. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 During PCI (all patients), outcome: 1.1 30-day mortality.
[Figure 5]
Figure 5. Funnel plot of comparison: 1 During PCI (all patients), outcome: 1.2 6-month mortality.
[Figure 6]
Figure 6. Funnel plot of comparison: 1 During PCI (all patients), outcome: 1.3 30-day mortality or myocardial infarction.
[Analysis 1.1]
Analysis 1.1. Comparison 1 During PCI (all patients), Outcome 1 30-day mortality.
[Analysis 1.2]
Analysis 1.2. Comparison 1 During PCI (all patients), Outcome 2 6-month mortality.
[Analysis 1.3]
Analysis 1.3. Comparison 1 During PCI (all patients), Outcome 3 30-day mortality or myocardial infarction.
[Analysis 1.4]
Analysis 1.4. Comparison 1 During PCI (all patients), Outcome 4 6-month mortality or myocardial infarction.
[Analysis 1.5]
Analysis 1.5. Comparison 1 During PCI (all patients), Outcome 5 30-day urgent revascularisation.
[Analysis 1.6]
Analysis 1.6. Comparison 1 During PCI (all patients), Outcome 6 6-month urgent revascularisation.
[Analysis 1.7]
Analysis 1.7. Comparison 1 During PCI (all patients), Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 1.8]
Analysis 1.8. Comparison 1 During PCI (all patients), Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 1.9]
Analysis 1.9. Comparison 1 During PCI (all patients), Outcome 9 30-day major bleeding.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 1 30-day mortality.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 2 6-month mortality.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 5 30-day urgent revascularisation.
[Analysis 2.6]
Analysis 2.6. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 6 6-month urgent revascularisation.
[Analysis 2.7]
Analysis 2.7. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 2.9]
Analysis 2.9. Comparison 2 Subgroup of PCI in patients with stable CAD, Outcome 9 30-day major bleeding.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 1 30-day mortality.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 2 6-month mortality.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 5 30-day urgent revascularisation.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 6 6-month urgent revascularisation.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 3.9]
Analysis 3.9. Comparison 3 Subgroup of PCI in patients with NSTEACS, Outcome 9 30-day major bleeding.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 1 30-day mortality.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 2 6-month mortality.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 5 30-day urgent revascularisation.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 6 6-month urgent revascularisation.
[Analysis 4.7]
Analysis 4.7. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 4.9]
Analysis 4.9. Comparison 4 Subgroup of primary PCI in patients with STEMI, Outcome 9 30-day major bleeding.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Subgroup of balloon angioplasty, Outcome 1 30-day mortality.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Subgroup of balloon angioplasty, Outcome 2 6-month mortality.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Subgroup of balloon angioplasty, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Subgroup of balloon angioplasty, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 5.5]
Analysis 5.5. Comparison 5 Subgroup of balloon angioplasty, Outcome 5 30-day urgent revascularisation.
[Analysis 5.6]
Analysis 5.6. Comparison 5 Subgroup of balloon angioplasty, Outcome 6 6-month urgent revascularisation.
[Analysis 5.7]
Analysis 5.7. Comparison 5 Subgroup of balloon angioplasty, Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 5.8]
Analysis 5.8. Comparison 5 Subgroup of balloon angioplasty, Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 5.9]
Analysis 5.9. Comparison 5 Subgroup of balloon angioplasty, Outcome 9 30-day major bleeding.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Subgroup of stent implantation, Outcome 1 30-day mortality.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Subgroup of stent implantation, Outcome 2 6-month mortality.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Subgroup of stent implantation, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Subgroup of stent implantation, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 6.5]
Analysis 6.5. Comparison 6 Subgroup of stent implantation, Outcome 5 30-day urgent revascularisation.
[Analysis 6.6]
Analysis 6.6. Comparison 6 Subgroup of stent implantation, Outcome 6 6-month urgent revascularisation.
[Analysis 6.7]
Analysis 6.7. Comparison 6 Subgroup of stent implantation, Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 6.8]
Analysis 6.8. Comparison 6 Subgroup of stent implantation, Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 6.9]
Analysis 6.9. Comparison 6 Subgroup of stent implantation, Outcome 9 30-day major bleeding.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 1 30-day mortality.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 2 6-month mortality.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 7.4]
Analysis 7.4. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 7.5]
Analysis 7.5. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 5 30-day urgent revascularisation.
[Analysis 7.6]
Analysis 7.6. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 6 6-month urgent revascularisation.
[Analysis 7.7]
Analysis 7.7. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 7 30-day mortality, myocardial infarction or urgent revascularisation.
[Analysis 7.8]
Analysis 7.8. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 8 6-month mortality, myocardial infarction or urgent revascularisation.
[Analysis 7.9]
Analysis 7.9. Comparison 7 Subgroup of PCI in patients pre-treated with clopidogrel, Outcome 9 30-day major bleeding.
[Analysis 8.1]
Analysis 8.1. Comparison 8 As initial medical treatment in patients with NSTEACS, Outcome 1 30-day mortality.
[Analysis 8.2]
Analysis 8.2. Comparison 8 As initial medical treatment in patients with NSTEACS, Outcome 2 6-month mortality.
[Analysis 8.3]
Analysis 8.3. Comparison 8 As initial medical treatment in patients with NSTEACS, Outcome 3 30-day mortality or myocardial infarction.
[Analysis 8.4]
Analysis 8.4. Comparison 8 As initial medical treatment in patients with NSTEACS, Outcome 4 6-month mortality or myocardial infarction.
[Analysis 8.5]
Analysis 8.5. Comparison 8 As initial medical treatment in patients with NSTEACS, Outcome 5 30-day major bleeding.